Clip Health’s product vision is to offer closed loop, consumer-centric and smartphone-connected healthcare solutions with rapid, accurate, decentralized diagnostics at the core.
Infectious disease testing and treatment
Testing and treatment for respiratory infections (COVID-19, influenza, strep throat), STIs (chlamydia, gonorrhea, trichomoniasis), and other infectious diseases.
Fertility, endocrinology & general wellness
Personalized hormone/protein testing & monitoring, with actionable lifestyle insights, in the fertility, endocrinology, metabolic, allergy, and inflammation healthscapes.
Chronic diseases: predictive monitoring
Companion diagnostics—after diagnosis or surgery or acute event—for cardiac diseases, cancer recurrence, autoimmune disorders, and other applications.
We have begun implementing this vision with COVID-19 and influenza, but will be developing solutions across infectious, metabolic, endocrine, and other chronic diseases and conditions.
We aim to offer complete solutions to problems our customers face. An accurate and rapid screening or diagnostic or monitoring test is a core part of it and the base of our solution stack. But we also close the loop by making the information ACTIONABLE. If we offer a test for a curable infectious disease, our app will also enable delivery of the therapeutic if you test positive. If we offer a test for a lifestyle condition, our app will also influence positive behavioral changes in the user.
COVID-19 + Flu Test
15-minute Rx home use test
Detection and differentiation of SARS-CoV-2, influenza A, and influenza B antigens from a self-collected nasal swab. Readout using the re-usable Core analyzer connected to the Clip Health iOS/Android app.
*In late development, pending FDA EUA submission
COVID-19 Point-of-care Test
30-minute point-of-care antigen test
EUA-authorized. Detection of SARS-CoV-2 nucleocapsid protein from anterior nares swab. Verified to detect the delta variant in symptomatic and asymptomatic individuals. Readout using Clip Analyzer, an iPhone-connected analyzer for high-volume point-of-care use.
Want to keep in touch?
Be the first to know about our products.
Sign up for updates on products, pre-orders, news & announcements, and all things Clip Health!
The Clip hardware and software leverage patented innovations in nanotechnology, materials chemistry, and signal processing to enable high-accuracy, cost-effective diagnostics.
Emergency Use Authorization (EUA) Disclaimer
© 2021 Luminostics, Inc. dba Clip Health In the USA, the Clip COVID Rapid Antigen Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for emergency use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet the requirements to perform high, moderate, or waived complexity tests. This test is for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. In the USA, the emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.